ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΠΎΠΌ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ½ Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²ΠΈΡΡΡΠ½ΡΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. Π§ΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 100% (Π½Π° Π²ΡΠ±ΠΎΡΠΊΠ΅ ΠΈΠ· 132 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ²), ΠΏΡΠ΅Π΄Π΅Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ (Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ 95%) ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 14, 10 ΠΈ 15 Π³Π΅Π½ΠΎΠΌ-ΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠΎΠ² Π΄Π»Ρ HIV-1, HBV ΠΈ HCV, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ·ΡΡΠ΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ²… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠΈΠ½ΡΡΡΠ΅ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΎΠ±Π·ΠΎΡ
- ΠΠ΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ: Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»ΠΈ ΠΈ ΠΈΡ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ
- Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ Π°Π³Π΅Π½ΡΠΎΠ², ΠΏΠ΅ΡΠ΅Π΄Π°ΡΡΠΈΡ ΡΡ ΡΠ΅ΡΠ΅Π· ΠΊΡΠΎΠ²Ρ
- ΠΠΈΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠΈΡΠΈΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (HIV)
- ΠΠΈΡΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (HCV)
- ΠΠΈΡΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π (HBV)
- Π’-Π»ΠΈΠΌΡΠΎΡΡΠΎΠΏΠ½ΡΠ΅ Π²ΠΈΡΡΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° I ΠΈ II ΡΠΈΠΏΠΎΠ² (HTLV-1,2)
- ΠΠΈΡΡΡ ΠΠΏΡΡΠ΅ΠΉΠ½Π°-ΠΠ°ΡΡ
- ΠΠΈΡΡΡΡ ΠΏΡΠΎΡΡΠΎΠ³ΠΎ Π³Π΅ΡΠΏΠ΅ΡΠ° 1 ΠΈ 2 ΡΠΈΠΏΠΎΠ²
- Π¦ΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡ
- ΠΠΈΡΡΡΡ Π³Π΅ΡΠΏΠ΅ΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 6, 7 ΠΈ 8 ΡΠΈΠΏΠΎΠ², ΠΏΠ°ΡΠ²ΠΎΠ²ΠΈΡΡΡ Π
- ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ
- ΠΠ΅ΡΠΎΠ΄Ρ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ
- Π‘Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ
- ΠΠ΅ΡΠΎΠ΄Ρ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠ΅ Π½Π° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΠΈ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ Π² ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π΅ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ
- ΠΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ ΠΏΠΎ «ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΡΠΎΡΠΊΠ΅»
- Π‘ΠΏΠΎΡΠΎΠ±Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠ΅ΠΉ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ
- ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ
- Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅
- ΠΠ΅ΡΠΎΠ΄ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ qPCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅
- ΠΠ±ΡΠ°Π±ΠΎΡΠΊΠ° Π΄Π°Π½Π½ΡΡ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ³Π½Π°Π»Π°
- ΠΡΠ±ΠΎΡ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΡ ΡΡΠ»ΠΎΠ²ΠΈΠΉ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ PCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅ ΠΈ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ
- ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½Π°Ρ PCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅
- ΠΡΠ±ΠΎΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠΈΡΠ΅Π½Π΅ΠΉ Π΄Π»Ρ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ½ΡΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄Π΅Π»ΠΎΠ² ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ½ΡΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠ°Π»ΠΈΠ±ΡΠΎΠ²ΠΎΡΠ½ΡΠ΅ ΠΊΡΠΈΠ²ΡΠ΅ Π΄Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ
- ΠΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΉ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ HIV-1, HBV ΠΈ HCV ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ qPCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅
- ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ qPCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅
ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΠΎΠΌ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅
.
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½Π° Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΡΠΌ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠΌ ΠΌΠ½ΠΎΠ³ΠΎΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠΌ ΠΏΠΎΠ»ΡΡΠ°ΡΡ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ³ΠΎ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π΄ΠΎ ΡΡΠ°Π΄ΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅Π΅ Π΅Ρ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ Π±ΡΠ΄Π΅Ρ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΠΏΠ΅ΡΠ΅Π΄Π°ΡΠΈ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ Π² ΠΊΡΠ°ΡΡΠ°ΠΉΡΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ Π²ΠΈΡΡΡΠ½ΡΡ Π½Π°Π³ΡΡΠ·ΠΊΡ Ρ ΡΠ΅Π»ΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ½ Π΄Π»Ρ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ ΡΠΈΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ Ρ ΠΌΠ½ΠΎΠ³ΠΎΡΡΠΎΡΠΎΠ½Π½Π΅ΠΉ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠ΅ΠΉ ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ Π΄ΡΡΠ³ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠΈΡΠ΅Π½Π΅ΠΉ.
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½ ΠΌΠ΅ΡΠΎΠ΄ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ PCR Π½Π° ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΠΎΠΌ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅ Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠ΅ΠΉ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Ρ ΠΎΠ΄Π½ΠΈΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΡΠΌ ΠΊΡΠ°ΡΠΈΡΠ΅Π»Π΅ΠΌ.
ΠΠ·ΡΡΠ΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΡΠ΅Π°ΠΊΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΌΠ΅ΡΠΈ, ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ½ΠΎ-Π²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ ΡΠ΅ΠΆΠΈΠΌΠΎΠ², ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ ΠΏΡΠ°ΠΉΠΌΠ΅ΡΠΎΠ² ΠΈ ΡΠ°Π·ΠΌΠ΅ΡΠ° Π³Π΅Π»Π΅Π²ΡΡ ΡΡΠ΅Π΅ΠΊ Π½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π½ΠΈΡ qPCR Π½Π° ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠ΅ ΠΈ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΡ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΡΡ ΡΠΈΠ³Π½Π°Π»ΠΎΠ².
Π‘ΠΎΠ·Π΄Π°Π½ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏ Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ Π²ΠΈΡΡΡΠΎΠ² Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ² Π, Π‘ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠΈΡΠΈΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° 1-Π³ΠΎ ΡΠΈΠΏΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ qPCR.
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ½ Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²ΠΈΡΡΡΠ½ΡΡ Π½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠ²ΡΡ ΠΊΠΈΡΠ»ΠΎΡ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. Π§ΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 100% (Π½Π° Π²ΡΠ±ΠΎΡΠΊΠ΅ ΠΈΠ· 132 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ²), ΠΏΡΠ΅Π΄Π΅Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ (Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ 95%) ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 14, 10 ΠΈ 15 Π³Π΅Π½ΠΎΠΌ-ΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠΎΠ² Π΄Π»Ρ HIV-1, HBV ΠΈ HCV, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.
ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΠΈ.
ΠΡΡΠ°ΠΆΠ°Ρ ΡΠ²ΠΎΡ Π³Π»ΡΠ±ΠΎΠΊΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ΅ΠΌΡ Π½Π°ΡΡΠ½ΠΎΠΌΡ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ. ΠΠ»Π°Π΄ΠΈΠΌΠΈΡΡ ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ²ΠΈΡΡ ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ²ΠΈΡΡ. Π― ΠΈΡΠΊΡΠ΅Π½Π½Π΅ ΠΏΡΠΈΠ·Π½Π°ΡΠ΅Π»Π΅Π½, ΠΠΌΠΈΡΡΠΈΡ ΠΡΡΠ΄ΡΠ½ΠΎΠ²Ρ, ΠΠ°ΠΊΡΠΈΠΌΡ ΠΠΎΠ½Π½ΠΈΠΊΠΎΠ²Ρ, Π‘Π΅ΡΠ³Π΅Ρ ΠΠ°ΠΏΠ΅, ΠΠ»ΡΠ³Π΅ ΠΠ½ΡΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΈ ΠΠ°ΡΠ°Π»ΡΠ΅ ΠΠ°Ρ Π°ΡΠΎΠ²ΠΎΠΉ Π·Π° ΠΏΠΎΠΌΠΎΡΡ Π² ΡΠ°Π±ΠΎΡΠ΅, ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ, ΡΠ΅Π½Π½ΡΠ΅ Π·Π°ΠΌΠ΅ΡΠ°Π½ΠΈΡ ΠΏΡΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈ ΡΡΠΊΠΎΠΏΠΈΡΠΈ Π΄ΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΠΈ, Π‘Π΅ΡΠ³Π΅Ρ ΠΠ°Π½ΡΠΊΠΎΠ²Ρ, ΠΠ΄ΡΠ°ΡΠ΄Ρ Π―ΠΊΠΎΠ²Π»Π΅Π²ΠΈΡΡ ΠΡΠ΅ΠΉΠ½Π΄Π»ΠΈΠ½Ρ — Π·Π° ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΡ ΠΌΠΈΠΊΡΠΎΡΠΈΠΏΠΎΠ² Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠΎΠ², Π‘Π΅ΡΠ³Π΅Ρ Π‘ΡΡΠΆΠΈΠΊΠΎΠ²Ρ ΠΈ ΠΡΠΈΠ½Π΅ ΠΡΠ΅ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²ΠΎΠΉ Π·Π° ΡΠΈΠ½ΡΠ΅Π· ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄ΠΎΠ², ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΡ Π‘Π΅ΡΠ³Π΅Π΅Π²ΠΈΡΡ ΠΠ°ΡΠ΅Π΄Π°ΡΠ΅Π»Π΅Π²Ρ Π·Π° ΠΏΠΎΠΌΠΎΡΡ ΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ.
1. Cotter S, M,. History of transfusion medicine, Adv. Vet. Sci. Comp. Med., 1991,36:1−8.
2. Bihl F., Castelli., Marineola F., Dodd R.Y., Brander C., Transfusion-transmittedinfections, Journal of Translational Medicine, 2007, 5:25−36.
3. Offergeld R., Ritter S., Hamouda O., The Risk of Transfusion Transmitted1. fections Current Aspects, Transfus. Med. Hemother., 2006, 33:130 134.
4. Goodnough L.T., Brecher M.E., Kanter M.H., and Aubuchon J.P. Transfusion.
5. Medicine: blood transfusion, N. Engl. J. Med., 1999, 340:438−447.
6. Guertler L.G., Virus safety of human blood, plasma, and derived products, 2002,.
7. Thrombosis research 107: 39−45.
8. Kottilil S., Jackson J.O., Polis M.A., Hepatitis B and hepatitis C in HIVinfection, 2005, Indian J. Med. Res., 121: 424−450.
9. Kim E.Y., Stanton J., Korber B.T., Krebs K., Bogdan D., Kunstman K., Wu S.,.
10. Phair J.P., Mirkin C.A., Wolinsky S.M., Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method, Nanomed., 2008, 3(3):293−303.
11. Meyers A., Chakauya E., Shephard E., Tanzer F.L., Maclean J., Lynch A.,.
12. Williamson A.L., Rybicki E.P., Expression of HIV-1 antigens in plants as potential subunit vaccines, BMC Biotechnol, 2008, 23(8):53−68.
13. Curran J.W., Jaffe H.W., Hardy A.M., Morgan W.M., Selik R.M., Dondero T.J.,.
14. Epidemiology of HIV Infection and AIDS in the United States, 1988, Science, 239:610−616.
15. Mills E.J., Kelly S., Bradley M., Mollon P., Cooper C., Nachega J.,.
16. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to.
17. AIDS or death: a meta-regression analysis, HIV Med., 2008 9(10):849−57.
18. Barnett D., Walker B., Landay A., Denny T.N., CD4 immunophenotyping in.
19. HIV infection, Nat. Rev. Microbiol., 2008, 6(11):S7−15.
20. Jarlais D.C., Semaan S., HIV prevention for injecting drug users: the first 25years and counting, Psychosom. Med., 2008, 70(5):606−611.
21. Sickinger E., Jonas G., Yem A.W., Goller A., Stieler M., Brennan C.,.
22. Liu G.J., Wang J.P., Xiao J.C., Zhao Z.W., Zheng Y.T., Preparation andcharacterization of three monoclonal antibodies against HIV-1 p24 capsid protein, Cel. l Mol. Immunol., 2007, 4(3):203−208.
23. Speth C., Bredl S., Hagleitner M., Wild J., Dierich M., Wolf H., Schroeder J.,.
24. Wagner R., Demi L., Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators of human monocytes, Virology, 2008, 382(l):46−58.
25. Anzinger J.J., Mezo I., Ji X., Gabali A.M., Thomas L.L., Spear G.T., HIVinfection of mononuclear cells is calcium-dependent, Virus Res., 2006, 122(1−2):183−188.
26. Monath T.P., Heinz F.X., Fields virology, 1996, 3rd ed. Philadelphia:1.ppincott-Raven Publishers.
27. Boonstra A., Woltman A.M., Janssen H.L., Immunology of hepatitis B andhepatitis C virus infections, Best Pract. Res. Clin. Gastroenterol., 2008, 22(6): 1049−1061.
28. Cui J., Kang X., Dai Z., Prediction of chronic hepatitis B, liver cirrhosis andhepatocellular carcinoma by SELDI-based serum decision tree classification, 2007, J Cancer Res Clin Oncol., 133(11):825−834.
29. Pol S., Mallet V.O., Improving anti-hepatitis C virus therapy, Expert Opin.
30. Biol. Ther., 2006, 6(9):923−933.
31. Ravera G., Bottaro L.C., Franceschini M., Morando A., Polo M., Zare M.,.
32. Giacopelli C., Zanardi S., Reliability and diagnostic use of a test for the search of the hepatitis C virus Ag (AgHCV), Hepatogastroenterology, 2006, 53(71):753−756.
33. Kessler H.H., Santner B.I., Umlauft F., Quantitation and genotyping of.
34. Hepatitis C virus RNA in sera of hemodialysis and AIDS patients, 1996, Clinical Diagnostic Virology, 5:73−78.
35. Orito E., Mizokami M., Nakano T., Serum hepatitis C virus RNA level as apredictor of subsequent response to interferon-a therapy, 1994, Journal of Medical Virology, 44:410−414.
36. Lee W. Hepatitis B Virus Infection., New England Journal of Medicine, 1997,337:1733−1745.
37. Tajiri H., Tanaka Y., Kagimoto S., Murakami J., Tokuhara D., Mizokami M.,.
38. Molecular evidence of father-to-child transmission of hepatitis B virus, J. Med. Virol. 2007. 79(7):922−926.
39. Palumbo E., Hepatitis B genotypes and response to antiviral therapy, Am J.
40. Ther., 2007, 14(3):306−399.
41. Beasley R.P., Hepatitis B virus the major etiology of hepatocellularcarcinoma, Cancer, 1988, 61:1942;1956.
42. Wong D., Cheung A.M., Orourke K., et al., Effect of alpha-interferontreatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis, Annals of Internal Medicine, 1993, 119:312−323.
43. Zuckerman A.J., Lavanchy D., Treatment options for chronic hepatitis: antivirals look promising, British Medical Journal, 1999, 319:799−800.
44. Oua J., Panb J., Nan Lina J.H., Transitional Cell Carcinoma in Dialysis.
45. Patients, Eur. Urol., 2000, 37(l):90−94.
46. Rodriguez-Frias F, Jardi R. Virologic markers of HBV infection, Gastroenterol.
47. Hepatol., 2006, 29 (2): 11−19.
48. Brown J.L., Carman W.F. and Thomas H.C., The clinical significance ofmolecular variation within the hepatitis B virus genome, 1992, Hepatology, 15:144−148.
49. Chen L., Liu F, Fan X., Gao J., Chen N., Wong T., Wu J., Wen S.W.,.
50. Detection of hepatitis B surface antigen, hepatitis B core antigen, and hepatitis B virus DNA in parotid tissues, Int. J. Infect. Dis., 2009, 13(l):20−23.
51. Jardi R., Rodriguez-Frias F., Schaper M., Giggi E., Tabernero D., Homs M.,.
52. Esteban R., Buti M., Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy, J, Hepatol., 2008, 49(5):695−701.
53. Palumbo E., Lamivudine for chronic hepatitis B: a brief review, Braz. J. Infect.
54. Dis., 2008, 12(5):355−357.
55. Slattery J.P., Franchini G., Gessain A., Genomic evolution, patterns of globaldissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses, Genome Res., 1999, 9:525−540.
56. Zunt J.R., Tapia K., Thiede H., Lee R., Hagan H., HTLV-2 infection ininjection drug users in King County, Washington, Scand. J. Infect. Dis., 2006, 38(8):654−663.
57. Yoshida M., Discovery of HTLV-1, the first human retrovirus, its uniqueregulatory mechanisms, and insights into pathogenesis, Oncogene, 2005, 24(39):5931−5937.
58. Burbelo P.D., Meoli E., Leahy H.P., Graham J., Yao K., Oh U., Janik J.E.,.
59. Mahieux R., Kashanchi F., Iadarola M.J., Jacobson S., Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Retrovirology, 2008, 5:96−102.
60. McGeoch D.J., Rixon F.J., Davison A .J., Topics in herpesvirus genomics andevolution, Virus Res., 2006, 117(1): 90−104.
61. Cheung A., Kieff E., Long internal direct repeat in Epstein-Barr virus DNAs, J.
62. Virol., 1982, 44: 286−294.
63. Norio P., Schildkraut C.L., Plasticity of DNA Replication Initiation in Epstein.
64. Barr Virus Episomes, PLoS Biol., 2004, 2(6):el52.
65. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Epstein.
66. Barr virus types 1 and 2 differ in the EBNA-3A, EBNA-3B, and EBNA-3C genes, J. Virol., 1990, 64: 4084−4092.
67. Amon W., Binne U.K., Bryant H., Jenkins P.J., Karstegl C.E., Farrell P.J., 1. tic cycle gene regulation of Epstein-Barr virus, J. Virol., 2004, 78(24): 13 460−13 469.
68. Gulley M.L., Tang W., Laboratory assays for Epstein-Barr virus-relateddisease, J. Mol. Diagn., 2008, 10(4):279−292.
69. Baringer J.R., Herpes simplex infections of the nervous system, Neurol. Clin., 2008, 26(3):657−674.
70. Batterson W., Roizman B., Characterization of the herpes simplex virionassociated factor responsible for the induction of genes, J. Virol., 1983, 46:371−377.
71. Brideau A., Enquist L., Tirabassi. R., The role of virion membrane proteinendocytosis in the herpesvirus life cycle, J. Clin. Virol., 2000, 17:69−82.
72. Mossman K.L., Ashkar A.A., Herpesviruses and the innate immune response.
73. Viral Immunol., 2005, 18(2):267−281.
74. Griffiths P.D., Walter S., Cytomegalovirus, Curr. Opin. Infect. Dis., 2005, 183.: 241−245.
75. McDonough S., Spector D., Transcription in human fibroblasts permissivelyinfected by human cytomegalovirus strain AD 169., Virology, 1983, 125:31−46.
76. Pancholi P., Wu F., Della-Latta P., Rapid detection of cytomegalovirusinfection in transplant patients, Expert Rev. Mol. Diagn., 2004, 4(2):231−242.
77. Gratacap-Cavallier B., Bonadona A., Berthier R., Brambilla E., Seigneurin.
78. J.M., Lorimier P., A simplified cytomegalovirus pp65 antigenemia assay procedure, J. Clin. Virol., 2003, 28(3):317−322.
79. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M.,.
80. Neff M.J., Gibran N.S., Huang M.L., Santo Hayes T.K., Corey L., Boeckh M., Cytomegalovirus reactivation in critically ill immunocompetent patients, JAMA, 2008, 300(4):413−422.
81. Maine G.T., Lazzarotto T., Landini M.P., New developments in the diagnosisof maternal and congenital CMV infection, Expert Rev. Mol. Diagn., 2001, 1(1): 19−29.
82. Oskay T., Karademir A., Ertiirk O.I., Association of anticonvulsanthypersensitivity syndrome with Herpesvirus 6, 7., Epilepsy Res., 2006, 70(l):27−40.
83. Levy J.A., Three new human herpesviruses (HHV6, 7, and 8), Lancet, 1997,349(9051):558−563.
84. Schleuning M., Jager G., Holler E., Hill W., Thomssen C., Denzlinger C.,.
85. Human parvovirus Π19 associated disease in bone marrow transplantation, Infection, 1999, 27:114−117.
86. Rebecca E., Lukehart S., Biological Basis for Syphilis, Clin Microbiol Rev.2006, 19(1):29—49.
87. Greer L., Wendel G.D., Rapid diagnostic methods in sexually transmittedinfections,. Infect. Dis. Clin. North Am., 2008, 22(4):601−617.
88. Ratnam S., The laboratory diagnosis of syphilis, Can. J. Infect. Dis. Med.
89. Microbiol., 2005, 16(1):45−51.
90. Wagner S. J, Transfusion-transmitted bacterial infection: risks, sources andinterventions, Vox Sang, 2004, 86(3): 157−163.
91. Greenwood Π., Fidock D., Kyle D., Kappe S., Alonso P., Collins F., Duffy P.,.
92. Malaria: progress, perils, and prospects for eradication, The Journal of Clinical Investigation, 2008, 118(4): 1266−1276.
93. Hellstern P., Solvent/detergent-treated plasma: composition, efficacy, andsafety, Curr. Opin. Hematol. 2004, ll (5):346−350.
94. Pelletier J.P., Transue S., Snyder E.L., Pathogen inactivation techniques, Best.
95. Pract. Res. Clin. Haematol., 2006, 19(l):205−242.
96. ΠΡΠΈΠΊΠ°Π· ΠΠΈΠ½ΠΈΡΡΠ΅ΡΡΡΠ²Π° ΠΠ΄ΡΠ°Π²ΠΎΠΎΡ ΡΠ°Π½Π΅Π½ΠΈΡ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ ΠΎΡ 4Π°Π²Π³ΡΡΡΠ° 2000 № 311 «Π ΠΌΠ΅ΡΠ°Ρ ΠΏΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΡΡΠ·ΠΈΠΉ».
97. ΠΠ³ΠΎΡΠΎΠ² A.M., ΠΡΠΈΠΏΠΎΠ² Π. Π., ΠΠ·Π°Π½ΡΠΈΠ΅Π² Π. Π., ΠΠ°Π²ΡΠΈΠ»ΠΎΠ²Π° Π. Π., Π’Π΅ΠΎΡΠΈΡ ΠΈΠΏΡΠ°ΠΊΡΠΈΠΊΠ° ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, Π.: ΠΡΡΡ. Π¨ΠΊ., 1991.
98. Lequin R., Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay.
99. ELISA), Clin. Chem., 2005, 51(12):2415−2418.
100. Magi B., Liberatori S., Immunoblotting techniques., Methods Mol. Biol., 2005,295:227−254.
101. Kurien B.T., Scofield R.H., Western blotting, Methods, 2006, 38(4):283−293.
102. Saiki R.K., Gelfand D.H., Stoffel S., Scharf S.J., Higuchi R., Horn, G.T., Mullis.
103. K.B., Erlich H.A. Primer-detected enzymatic amplification of DNA with a thermostable DNA polymerase, Science, 1988, 239:487−491.
104. Innis MA., PCR protocols: a guide to method and applications, London, 1. Academic Press 1990.
105. Berger A., Preiser W., Viral genome quantification as a tool for improvingpatient management: the example of HIV, HBV, HCV and CMV, Journal of Antimicrobial Chemotherapy, 2002, 49: 713−721.
106. Allain J, P,. Genomic screening for blood-borne viruses in transfusion settings,.
107. Clin. Lab. Haematol., 2000, 22(1): 1−10.
108. Larzul D., Guigue F., Sninsky J.J., Mack D.H., Brechot C., Guesdon J.L.,.
109. Detection of hepatitis B virus sequences in serum by using in vitro enzymatic amplification, J. Virol. Methods, 1988, 20(3):227−237.
110. Garson J.A., Ring C., Tuke P., Tedder R.S., Enhanced detection by PCR ofhepatitis C virus RNA, Lancet, 1990, 336(8719):878−879.
111. Compton J., Nucleic Acid Sequence-Based Amplification, Nature, 1991, 350:91.92.
112. Fahy E., Kwoh D.Y., Gingeras T.R., Self-sustained Sequence Replication3SR): An isothermal transcription-based amplification system alternative to PCR. PCR Methods and Applications, 1991, 1: 25−33.
113. Chandra M., Keller S., Gloeckner C., Bornemann B., Marx A., New branched.
114. DNA constructs, Chemistry, 2007, 13(12):3558−3564.
115. Tehe A., Maurice C., Hanson D., Borget M., Abiola N., Maran M.,.
116. Quantification of HIV-1 p24 by a highly improved ELISA: Analternative to HIV-1 RNA based treatment monitoring, J Clin Virol., 2006, 37(3): 199−205.
117. Rotheram-Borus M.J., Leibowitz A.A., Etzel M.A., Routine, rapid HIV testing,.
118. AIDS Educ Prev., 2006, 18(3):273−280.
119. Dohner K., Radtke K., Schmidt S., Sodeik B., Eclipse phase of herpes simplexvirus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26, J Virol., 2006,80(16):8211−8224.
120. Murphy G., Parry J. V., Assays for the detection of recent infections withhuman immunodeficiency virus type 1, Eurosurveillance, 2008, 13(36):4−10.
121. Vernet G., Molecular diagnostics in virology, J. Clin. Virol., 2004, 31(4):239 247.
122. Lelie P.N., van Drimmelen H.A., Cuypers H.T., Best S.J., Stramer S.L.,.
123. Sensitivity of HCV RNA and HIV RNA blood screening assays, Transfusion, 2002, 42(5):527−536.
124. Koppelman M.H., Sjerps M.C., Reesink H.W., Cuypers H.T., Evaluation of.
125. COBAS AmpliPrep nucleic acid extraction in conjunction with COB AS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection, Vox Sang, 2005, 89(4): 193−200.
126. Katsoulidou A., Moschidis Z., Sypsa V., Chini M., Papatheodoridis G.V.,.
127. Tassopoulos N.C., Mimidis K., Karafoulidou A., Hatzakis A., Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load, Vox Sang. 2007, 92(1):8−14.
128. Ginocchio C.C., Kemper M., Stellrecht K.A., Witt D.J., Multicenter evaluationof the performance characteristics of the NucliSens HIV-1 QT assay used for quantitation of human immunodeficiency virus type 1 RNA, J. Clin. Microbiol., 2003, 41(l):164−73.
129. Elbeik T., Markowitz N., Nassos P., Kumar U., Beringer S., Haller B., Ng V.,.
130. Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow, J. Clin. Microbiol., 2004, 42(7):3120−3127.
131. Higuchi, R., Dollinger, G., Walsh, P. S., Griffith, R., Simultaneousamplification and detection of specific DNA-sequences, Bio-Technology, 1992,10(4): 413−417.
132. Wittwer C. T., Herrmann M. G., Moss A. A. and Rasmussen R. P., Continuousfluorescence monitoring of rapid cycle DNA amplification, BioTechniques, 1997, 22:134−138.
133. Skeidsvoll J. and Ueland P. M., Analysis of Double-Stranded DNA by.
134. Capillary Electrophoresis with Laser-Induced Fluorescence Detection Using the Monomeric Dye SYBR Green I, Anal. Biochem., 1995, 231:359−365.
135. Tseng S. Y., Macool D., Elliott V., Tice G., Jackson R., Barbour M. and.
136. Amorese D., An homogeneous fluorescence polymerase chain reaction assay to identify Salmonella, Anal. Biochem., 1997, 245:207−212.
137. Morrison T. B., Weis J. J. and Wittwer C. T., Quantification of low-copytranscripts by continuous SYBR Green I monitoring during amplification, BioTechniques, 1998, 24:954−958.
138. Newton C. R., Graham A., Heptinstall L. E., Powell S. J., Summers C.,.
139. Kalsheker N., Smith J. C. and Markham A. F., Analysis of any point mutation in DNA, The amplification refractory mutation system (ARMS), Nucleic Acids Res., 1989, 25: 2503−2516.
140. Gibellini D., Gardini F., Vitone F., Schiavone P., Furlini G., Re M.C.,.
141. Simultaneous detection of HCV and HIV-1 by SYBR Green real time multiplex RT-PCR technique in plasma samples, Mol. Cell Probes., 2006, 20: 223−229.
142. Didenko V., DNA Probes Using Fluorescence Resonance Energy Transfer.
143. FRET): Designs and Applications, Biotechniques, 2001, 31(5): 11 061 121.
144. Ranasinghe R.T. and Brown T., Fluorescence based strategies for geneticanalysis, Chem. Commun, 2005, 28(44): 5487 5502.
145. Nazarenko I. A., Bhatnagar S. K. and Hohman R. J., A closed tube format foramplification and detection of DNA based on energy transfer., Nucleic Acids Res., 1997, 25(12): 2516−2521.
146. Nuovo G. J., Hohman R. J., Nardone G. A. and Nazarenko I. A., In Situ.
147. Amplification Using Universal Energy Transfer-labeled Primers, J. Histochem. Cytochem., 1999, 47:273−280.
148. Asselbergs F.A., Widmer R., Rapid detection of apoptosis through real-timereverse transcriptase polymerase chain reaction measurement of the small cytoplasmic RNA Yl, Anal Biochem., 2003, 318(2):221−229.
149. Bengra, C., Mifflin, T.E., Khripin, Y., Manunta, P., Williams, S.M., Jose,.
150. P.A., and Felder, R.A., Genotyping of essential hypertensionsinglenucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers, Clin. Chem., 2002, 48:2131−2140.
151. Warden D.R. and Refsum H., Detection of Single-Nucleotide Polymorphismsby PCR with Universal Energy Transfer-Labeled Primers: Application to Folateand Cobalamin-Related Genes, Clin. Chem., 2005, 51: 17 131 716.
152. Nazarenko I., Homogeneous detection of nucleic acids using self-quenchedpolymerase chain reaction primers labeled with a single fluorophore (LUX primers), Methods Mol. Biol., 2006, 335:95−114.
153. Kusser W., Use of self-quenched, fluorogenic LUX primers for geneexpression profiling, Methods Mol. Biol., 2006, 335:115−133.
154. Huygens F., Inman-Bamber J., Nimmo G.R., Munckhof W., Schooneveldt J.,.
155. Harrison B., McMahon J.A., Giffard P.M., Staphylococcus aureus genotyping using novel real-time PCR formats, J. Clin. Microbiol., 2006, 44(10):3712−3719.
156. KandimallaE.R., Agrawal S., 'Cyclicons' as hybridization-based fluorescentprimer-probes: synthesis, properties and application in real-time PCR, Bioorg. Med. Chem., 2000, 8(8): 1911;1916.
157. Fiandaca M.J., Hyldig-Nielsen J.J., Gildea B.D., Coull J.M., Self-reporting.
158. PNA/DNA primers for PCR analysis, Genome Res., 2001, 1(4):609−613.
159. Latorra D., Campbell K., Wolter A., Hurley J.M., Enhanced allele-specific.
160. PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers, Hum. Mutat., 2003, 22(l):79−85.
161. Strerath M., Detmer I., Gaster J., Marx A., Modified oligonucleotides as toolsfor allele-specific amplification, Methods Mol. Biol., 2007, 402:317−328.
162. Holland P.M., Abramson R.D., Watson R., Gelfand D.H., Detection ofspecific polymerase chain reaction product by utilizing the 5'-3'exonuclease activity of Thermus aquaticus DNA polymerase, Proc. Natl. Acad. Sei. U S A., 1991, 88(16):7276−7280.
163. Letertre C., Perelle S., Dilasser F., Arar K., Fach P., Evaluation of theperformance of LNA and MGB probes in 5'-nuclease PCR assays, Mol. Cell Probes., 2003, 7(6):307−311.
164. Piccirilli J.A., Krauch T., Moroney S.E. and Benner S.A., Enzymaticincorporation of a new base pair into DNA and RNA extends the genetic alphabet, Nature, 1990, 343: 33−37.
165. Moser M.J., Marshall D.J., Grenier J.K., Kieffer C.D., Exploiting the.
166. Enzymatic Recognition of an Unnatural Base Pair to Develop a Universal Genetic Analysis System, Clin. Chem., 2003, 49:407−414.
167. Moser M.J. and Prudent J.R., Enzymatic repair of an expanded geneticinformation system, Nucleic Acids Research, 2003, 31(17): 5048−5053.
168. Krenke B.E., Nassif N., Sprecher C.J., Knox C., Schwandt M., Storts D.R.,.
169. Developmental validation of a real-time PCR assay for the simultaneous quantification of total human and male DNA, Genetics, 2008, 3(1): 14−21.
170. Atallah Z. K., Bae J., Jansky S. H., Rouse D. I., and Stevenson W. R.,.
171. Multiplex Real-Time Quantitative PCR to Detect and Quantify Verticillium dahliae Colonization in Potato Lines that Differ in Response to Verticillium Wilt, Phytopathology, 2007, 97(7): 865−872.
172. Moser M.J., Christensen D.R., Norwood D. and Prudent J.R., Multiplexed.
173. Detection of Anthrax-Related Toxin Genes, J. Mol. Diagn., 2006, 8(1): 89−96.
174. Marras S.A., Tyagi S., Kramer F.R., Real-time assays with molecular beaconsand other fluorescent nucleic acid hybridization probes, Clin. Chim. Acta., 2006, 363(l-2):48−60.
175. Escaja N., Gomez-Pinto I., Rico M., Pedroso E., Gonzalez C., Structures andstabilities of small DNA dumbbells with Watson-Crick and Hoogsteen base pairs, Chembiochem., 2003, 4(7):623−632.
176. Crey-Desbiolles C., Ahn D.R., Leumann C.J., Molecular beacons with ahomo-DNA stem: improving target selectivity, Nucleic Acids Res., 2005, 33(8):e77.
177. Thelwell N., Millington S., Solinas A., Booth J., Brown T., Mode of actionand application of Scorpion primers to mutation detection, Nucleic Acids Res., 2000, 28(19):3752−3761.
178. Solinas A., Brown L.J., McICeen C., Mellor J.M., Nicol J., Thelwell N.,.
179. Brown T., Duplex Scorpion primers in SNP analysis and FRET applications, Nucleic Acids Res., 2001, 29(20):E96.
180. Li Q., Luan G., Guo Q., Liang J., A new class of homogeneous nucleic acidprobes based on specific displacement hybridization, Nucleic Acids Res., 2002, 30(2):E5.
181. Wolff D., Gerritzen A., Comparison of the Roche COBAS Amplicor Monitor,.
182. Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Testassays for quantification of hepatitis C virus and HIV RNA, Clin. Chem. Lab. Med., 2007, 45(7):917−922.
183. Gueudin M., Plantier J.C., Lemee V., Schmitt M.P., Chartier L., Bourlet T.,.
184. Ruffault A., Damond F., Vray M., Simon F., Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes, J. Acquir. Immune. Defic. Syndr., 2007, 44(5):500−505.
185. Sarrazin C., Dragan A., Gartner B.C., Forman M.S., Traver S., Zeuzem S.,.
186. Valsamakis A., Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA, J. Clin. Virol., 2008, 43(2): 162−168.
187. Romano J.W., van Gemen B., Kievits T., NASBA: a novel, isothermaldetection technology for qualitative and quantitative HIV-1 RNA measurements, Clin. Lab. Med., 1996, 6(1):89−103.
188. Deiman B., Jay C., Zintilini C., Vermeer S., van Strijp D., Venema F., Van de.
189. Wiel P., Efficient amplification with NASBA of hepatitis B virus, herpes simplex virus and methicillin resistant Staphylococcus aureus DNA, J. Virol. Methods., 2008, 51(2):283−293.
190. Yates S., Penning M., Goudsmit J., Frantzen I., van de Weijer B., van Strijp.
191. D., van Gemen B., Quantitative detection of hepatitis B virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection, J. Clin. Microbiol., 2001, 39(10):3656−3665.
192. Rubina A.Yu., Pankov S.V., Dementieva E.I., Penkov D.N., Butygin A.V.,.
193. Vasiliskov V.A., Chudinov A.V., Mikheikin A.L., Mikhailovich V.M., and Mirzabekov A.D., Hydrogel drop microchips with immobilized DNA: properties and methods for large-scale production, Analytical Biochemistry, 2004, 325:92−106.
194. Finney, D.J., Probit Analysis, 1971, Cambridge University Press, ISBN052108041X, p. 333.
195. Larionov A., Krause A., Miller W., A standard curve based method forrelative real time PCR data Processing, BMC Bio informatics, 2005, 6:6278.
196. Strizhkov B.N., Drobyshev A.L., Mikhailovich V.M., Mirzabekov A.D., PCRamplification on a microarray of gel-immobilized oligonucleotides: detection of bacterial toxinand drug-resistant genes and their mutations. Biotechniques, 2000, 29(4):844−854.